Showing results (971-980 of 1,812) with videos related to

Sort By:
Pageof 182
Pulmonary Circulation|September 12, 2022
Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: An in vivo study utilizing MacitentanGerard Murphy, Geeshath Jayasekera, James Mullin, et al.
Pulmonary Circulation|July 28, 2012
Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunctionVinicio A de Jesus Perez, Francois Haddad, Roham T Zamanian
Pulmonary Circulation|July 28, 2012
Group V phospholipase A(2) increases pulmonary endothelial permeability through direct hydrolysis of the cell membraneNilda M Muñoz, Anjali Desai, Lucille N Meliton, et al.
Pulmonary Circulation|July 28, 2012
Activation of the unfolded protein response is associated with pulmonary hypertensionMichael E Yeager, Monica B Reddy, Cecilia M Nguyen, et al.
Pulmonary Circulation|January 3, 2025
Differences in Pulmonary Artery Flow Hemodynamics Between PAH and PH-HFpEF: Insights From 4D-Flow CMRBong-Joon Kim, Jeesoo Lee, Haben Berhane, et al.
Pulmonary Circulation|January 2, 2025
Common Variable Immunodeficiency Associated With Noninfectious Pulmonary Complications and Its Treatment: Beyond Immunoglobulin TherapyAustin J Parsons, Domingo Franco-Palacios, Bryan Kelly, et al.
Pulmonary Circulation|December 30, 2024
Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertensionCara Morgan, Nikmah Idris, Kathy Elterefi, et al.
Pulmonary Circulation|April 4, 2025
Hank the Heart and Animation-Based Education for Pulmonary HypertensionMichelle Cash, Barbara Giambra, Lara Stone, et al.
Pulmonary Circulation|December 5, 2024
SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantationRobert P Frantz, Shashank S Desai, Gregory Ewald, et al.
Pulmonary Circulation|December 11, 2024
Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertensionP Vitulo, L Piccari, S J Wort, et al.
Pageof 182